Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Treating patients with poor-risk cytogenetics with venetoclax and HMAs

Daniel Pollyea • 10 Dec 2021
ASH 2021
Acute Myeloid Leukemia Azacitidine Decitabine Venetoclax

Daniel Pollyea, MD, MS, University of Colorado, Denver, CO, discusses outcomes of treatment-naïve patients with acute myeloid leukemia (AML) with poor-risk cytogenetics or poor-karyotype treated with venetoclax and hypomethylating agents (HMAs). Data from a Phase III (NCT02993523) and Phase Ib trial (NCT02203773) were analyzed, where patients received venetoclax with azacitidine and venetoclax with decitabine respectively. Having a poor-risk cytogenetics profile was not found to affect outcomes, whereas the presence of TP53 mutations worsened outcomes. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Daniel Pollyea

1:08
The importance of predicting venetoclax response in patients with AML
Daniel Pollyea • 7 Sep 2023
1:11
Varied outcomes in patients with AML harboring poor-risk cytogenetics with or without TP53 mutation
Daniel Pollyea • 7 Sep 2023
1:00
The potential use of multi-gene molecular MRD testing in AML
Daniel Pollyea • 7 Sep 2023
1:13
Addressing whether AML with monocytic features should be considered a distinct clinical entity
Daniel Pollyea • 7 Sep 2023

Related Videos

1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
3:34
Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias
Anthony Stein • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals